Active substance
Neomycin
- SFDA 2
- US FDA 14
- US price lines 1
- Safety 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NEOMYCIN NASAL SPRAY | 0.5 % | Nasal drops, solution · Nasal use | 1 Nasal Applicator | SAR 2.40 | NCE · Prescription | LABORATORIES AVENTIS (USIPHER) | Withdrawn by MAH · Not Marketed |
| STATROL EYE DROPS | 3.5 mg | Eye drops, solution · Ocular use | 1 Dropper Container | SAR 10.85 | Generic · Prescription | ALCON COUVREUR | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NEOMYCIN SULFATE | 500MG | tablet · oral | TEVA | Prescription | 2 Sep 1964 |
| NEOMYCIN SULFATE | 500MG | tablet · oral | AMVIKA | Prescription | 28 Jul 2006 |
| NEOMYCIN SULFATE | 500MG | tablet · oral | LANNETT | Discontinued | 26 Oct 1966 |
| NEO-RX | 100% | powder · for rx compounding | X GEN PHARMS | Discontinued | 5 Jan 1972 |
| NEO-FRADIN | EQ 87.5MG BASE/5ML | solution · oral | X GEN PHARMS | Discontinued | 23 May 2002 |
| MYCIFRADIN | EQ 87.5MG BASE/5ML | solution · oral | PHARMACIA AND UPJOHN | Discontinued | 13 Mar 2009 |
| NEOMYCIN SULFATE | 500MG | tablet · oral | PHARMOBEDIENT | Discontinued | 29 Mar 2010 |
| NEOMYCIN SULFATE | 500MG | tablet · oral | CHARTWELL MOLECULAR | Discontinued | 10 Jun 2016 |
| NEOMYCIN SULFATE | 500MG | tablet · oral | BRISTOL MYERS SQUIBB | Discontinued | |
| NEOMYCIN SULFATE | 500MG | tablet · oral | LILLY | Discontinued | |
| NEOBIOTIC | EQ 350MG BASE | tablet · oral | PFIZER | Discontinued | |
| MYCIFRADIN | EQ 350MG BASE | tablet · oral | PHARMACIA AND UPJOHN | Discontinued | |
| NEOMYCIN SULFATE | 500MG | tablet · oral | SANDOZ | Discontinued | |
| NEOMYCIN SULFATE | 500MG | tablet · oral | ROXANE | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NEOMYCIN 500 MG TABLET | $0.83308 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 8 Aug 2025 CORTISPORIN — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 8 Aug 2025 CORTISPORIN — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 8 Aug 2025 CORTISPORIN — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 14 May 2021 MAXITROL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 May 2021 MAXITROL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 May 2020 NEOSPORIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 5 Jan 2019 COLY-MYCIN S — safety-related labeling change
Labeling sections changed: Adverse Reactions
Combinations containing Neomycin
- Bacitracin + neomycin
- Betamethasone + neomycin
- Dexamethasone + neomycin
- Flumetasone pivalate + neomycin
- Fluocinolone + neomycin
- Fluromethelon + neomycin
- Hydrocortisone + neomycin
- Methylprednisolone + neomycin
- Neomycin + polymyxin b
- Bacitracin + neomycin + polymyxin b
- Bufexamac + neomycin + nystatin
- Centella extract + hydrocortisone + neomycin
- Dexamethasone + neomycin + polymyxin b
- Gramicidin + neomycin + nystatin
- Gramicidin + neomycin + polymyxin b
- Hydrocortisone + natamycin + neomycin
- Hydrocortisone + neomycin + polymyxin b
- Neomycin + nystatin + polymyxin b
- Neomycin + polymyxin b + prednisolone
- Bacitracin + neomycin + polymyxin b + zinc oxide
- Gramicidin + neomycin + nystatin + triamcinolone
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.